Michael L. Baum

Attorney Profile

Top Rated Class Action & Mass Torts Attorney in Los Angeles, CA

Baum, Hedlund, Aristei & Goldman, PC
 | 10940 Wilshire Blvd., 17th Floor
Los Angeles, CA 90024
Phone: 310-207-3233
Fax: 310-820-7444
Selected To Super Lawyers: 2005, 2012 - 2021
Licensed Since: 1985
Practice Areas:
  • Class Action/Mass Torts: Plaintiff (60%),
  • Personal Injury - Products: Plaintiff (40%)
    Attorney Profile

    Michael L. Baum is the senior managing partner of Baum, Hedlund, Aristei & Goldman. He has successfully led the firm through thousands of wrongful death and personal injury cases stemming from major pharmaceutical drug catastrophes, harmful consumer products, and commercial transportation mass disasters.

    He began his career more than 30 years ago, primarily handling airline accidents and other commercial transportation disasters as well as some pharmaceutical product liability litigation. While he oversees all aspects of managing the firm, Michael directs all of the firm’s mass tort litigation, including defective or harmful pharmaceutical drugs, medical devices, herbicides, and consumer products. He also oversees our class actions and whistleblower qui-tam actions.

     “Some of our staff were friends long before they started working here and they remain friends after almost three decades of working together. They actually like each other and enjoy making a difference in the lives of others. One of my favorite quotes, which I like to recite to my staff, sums up the work environment we’ve created at the firm: ‘In every job that must be done, there is an element of fun. You find the fun, and – SNAP – the job’s a game!’”

    Award-Winning Pharmaceutical Litigation Team

    Under Michael’s leadership, Baum Hedlund has developed a reputation as a law firm that can be counted upon to go above and beyond what is needed to get the job done, a firm that has successfully litigated personal injury, wrongful death and consumer fraud cases against major pharmaceutical companies such as Alpha Therapeutic, Armour Pharmaceutical Co., Baxter Health Care Corp, Bayer Corp., Dalkon Corporation, Eli Lilly, Forest Labs, GlaxoSmithKline, and Pfizer.

    In 1999, Michael served on the trial team in the only Hemophiliac AIDS case to go before a jury. Michael and the trial team represented Leo and Shirley Dixon, whose son, Ken Dixon, contracted the HIV virus and AIDS allegedly as a result of using hemophilia medication contaminated with HIV.

    Evidence presented at trial showed the medication Ken Dixon used was plasma‑derived medication contaminated from the use of high-risk donors with the HIV virus. The jurors found that two of the medication manufacturers, Cutter Biological and Alpha Therapeutics, were strictly liable for product liability, negligence, and fraud. The jurors further found that after Ken Dixon initially was infected with the AIDS virus (which was not known to him at the time), the continued use of the contaminated products further aggravated Ken’s condition, exacerbating and accelerating the development of AIDS. The jury awarded Leo and Shirley Dixon $35.3 million in survival and wrongful death damages. Although the judge overturned the verdict based on a technical issue, the verdict provided essential justice for not only the Dixon family but for hemophiliacs across the country who have suffered and died as a result of their HIV-infected medication.

    Fast-forward twenty years later, to find Michael continuing to fight for those injured by Big Pharma products. The National Law Journal recognized Michael and his team as 2018 Elite Trial Lawyers and Pharmaceutical Litigation first place winners for their unprecedented jury verdict against a brand-name drug manufacturer (GSK) for the wrongful death of a man who took a generic form of Paxil.

    Groundbreaking Verdicts in Monsanto Roundup Litigation

    Michael served on the trial team for three of the first Monsanto Roundup lawsuits to go before juries. In the first trial, Michael and a team of lawyers represented Dewayne “Lee” Johnson, a Benicia, California school district groundskeeper, who alleged exposure to Monsanto herbicides caused him to develop terminal non-Hodgkin lymphoma. A jury in San Francisco unanimously awarded Mr. Johnson $289M in compensatory and punitive damages, finding that Monsanto acted with malice, oppression, or fraud.

    In the wake of this groundbreaking verdict, The National Trial Lawyers Top 100 recognized Michael and his team as the 2019 Trial Team of the Year in the Mass Torts category.

    The second Roundup lawsuit to proceed to trial, Hardeman v. Monsanto Company, resulted in an $80 million jury verdict. In May of 2019, the third Roundup cancer trial culminated in a historic $2.055 billion verdict in favor of a Bay Area couple who alleged years of exposure to Roundup weed killer caused them to develop non-Hodgkin lymphoma. 

    Holding Companies Responsible for Aviation Disasters

    In addition, his firm is known for successfully resolving major transportation disaster cases against companies such as Airbus, Alaska Airlines, American Airlines, Amtrak, Bell Helicopter Co., Beechcraft, Boeing, Cessna, China Eastern Airlines, Continental Airlines, Delta Airlines, EgyptAir, Ford Motor Co., McDonnell Douglas, Piper, Robinson Helicopter Co., Sikorsky, SwissAir, TACA Airlines, TWA, United Airlines, and US Airways, among many others.

    As part of the plaintiffs’ trial team for families who lost loved ones in the United 232 Sioux City, Iowa, crash, Michael found the smoking gun document that showed General Electric’s engineers’ graphs predicting the next DC 10 engine failure, which happened to be the date of the United 232 crash five years later.

    “Rigorously investigating and litigating the types of devastating cases we handle on a daily basis requires relentless focus and dedication to our clients’ causes. Approaching things from the perspective that every problem has an optimum solution waiting to be apprehended simplifies our team’s outlook on every aspect of each case we handle.” 

    Influencing Public Policy

    Michael was invited to speak before governmental and regulatory entities on several occasions concerning serious health hazards exposed, in part, due to his firm’s litigation. He testified in Brussels at a public hearing before the European Parliament’s Special Committee Hearing on the EU’s authorization procedure for pesticides (PEST), concerning environment impacts of pesticides, including Monsanto’s Roundup weed killerHe and Robert F. Kennedy, Jr. delivered the keynote address to members of the European Green Party at the start of their pesticides hearing during that same trip. He and his partner, R. Brent Wisner, also briefed members of Parliament of Canada’s Green Party about the first Roundup cancer verdict we helped obtain, as well as the evidence we presented at that trial.

    Medical officials from foreign governments in countries such as Ireland, Japan, Russia, and Taiwan have sought Michael’s advice and assistance with their countries’ public policies concerning consumer drug safety. They’ve done so after becoming aware of Michael’s impressive understanding of biomedical research, clinical trials, statistics, the pharmaceutical industry and marketing, as well as his firm’s successful and effective discovery procedures and extensive work with experts on complicated scientific issues related to Baum Hedlund’s pharmaceutical litigation. 

    Career Highlights

    Among his many achievements, accomplished with the help of his team, Michael is most proud of:

    • Being recognized, along with his firm, as a national leader in the antidepressant Paxil, Prozac, and Zoloft suicide litigation;
    • Working to bring about the black box suicidality warning for children and young adults, now on most antidepressant labels;
    • Helping spur funding for the Ricky Ray Hemophilia Relief Fund Act of 1998, which was made part of the negotiated settlement to help scores of hemophiliacs infected with HIV by contaminated medication;
    • Arranging for the face-to-face presentation between pharmaceutical company executives and dozens of hemophiliac families that got to say, person by person, holding before and after photos of themselves or departed loved ones, how the hemophilia-AIDS epidemic, and the manner in which the companies caused and covered it up, impacted their lives;
    • Being one of the leaders in the fight against federal preemption, a doctrine pushed by the pharmaceutical industry to wipe out consumers’ rights to sue drug companies for injuries caused by their drugs (Preemption was finally defeated in 2009 with the Supreme Court’s ruling in Wyeth v. Levine);
    • Creating the first class action ever filed against an SSRI-antidepressant manufacturer, ending with the successful resolution of more than 3,000 Paxil injury cases;
    • Finding “needles in haystacks” and “smoking guns” in document productions, such as GE engineers’ graphs predicting the next DC 10 engine failure which mirrored the date of the United 232 crash five years later, an internal study linking SSRIs to cardio birth defects, or documentation of company programs to ghostwrite medical journal articles for academic opinion leaders to give the appearance of objective science when actually serving marketing objectives to increase prescriptions, i.e. disguised advertising;
    • Negotiating the first official public apology by an airline for the 2003 Air Midwest Flt. 5481 Charlotte, North Carolina crash;
    • Eliminating California law that protected tobacco companies from lawsuits.  For many years, the statute of limitations was considered to begin to run from the date the plaintiff knew or should have known that he/she was addicted to tobacco.  This effectively barred plaintiffs, many of whom began smoking in their teens, from suing.  Now, the statute of limitations runs when the plaintiff’s physical injuries are (or reasonably could be) discovered;
    • Developing a rigorous, skillful, and technical method for locating hard-to-find manufacturer documents in order to successfully litigate against major pharmaceutical companies, positioning his firm as a leader in the fight to increase public health and safety;
    • Creating coalitions of activists, attorneys, and Baum Hedlund staff, who work together to resolve global problems caused by harmful and defective drugs, which no individual could accomplish alone.

    “We have adopted Margaret Mead’s philosophy, ‘Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.’”

    Michael has served on numerous trial teams and plaintiffs’ steering committees in mass tort litigation involving pharmaceutical product liability cases as well as major airline crashes.

    He has an AV® 5.0 out of 5 Peer Review Rating through Martindale Hubbell, and is listed in The Best Lawyers in America®, Bar Register of Preeminent Lawyers, Southern California Super Lawyers, Who’s Who in American Law, and Aviation Counsel Magazine’s List of Recommended High Flyers.

    In his spare time, Michael enjoys spending time with his family, playing foosball, softball, volleyball, and boogie boarding.

    ---------------------

     

    Baum Hedlund has taken on the Zantac cancer litigation after the U.S. Food and Drug Administration (FDA) announced that it is investigating Zantac cancer risks after testing of certain Zantac (ranitidine hydrochloride) tablets found the commonly-used heartburn medication contains a cancer-causing chemical up to 3,000 times greater than the FDA’s daily intake limit. The carcinogenic chemical present in Zantac is known as N-nitrosodimethylamine (“NDMA”). Though the FDA has yet to issue an official Zantac recall, CVS and Walgreens have pulled Zantac and Zantac OTC generics from their shelves and Apotex has voluntarily recalled its ranitidine products from Rite-Aid and Walgreens.   

     
    Practice Areas
    • 60%Class Action/Mass Torts: Plaintiff
    • 40%Personal Injury - Products: Plaintiff
    Focus Areas

    Class Actions, Toxic Torts, Medical Devices, Pharmaceutical, Products Liability

    Selections

    Selected to Super Lawyers for 11 yearsbottom-image

    Super Lawyers: 2005, 2012 - 2021

    Email Me

    To: Michael L. Baum
    Super Lawyers: Potential Client Inquiry

    Disclaimer »
    Privacy Policy »

    Michael Baum of Baum, Hedlund, Aristei & Goldman, P.C., started practicing law to help people stand up to the companies, individuals and corporations who caused them harm. Discover your legal options at 800-827-0087 or at www.baumhedlundlaw.com.

    View all videos for this attorney »

    About Michael Baum

    Admitted: 1985, California

    Professional Webpage: https://www.baumhedlundlaw.com/attorneys/michael-l-baum/

    Honors/Awards:

    • The National Trial Lawyers Top 100 recognized the law firms of Baum, Hedlund, Aristei & Goldman, the Miller Firm and Audet & Partners with the 2019 Trial Team of the Year award (in the Mass Torts category) for their work in the groundbreaking case of Dewayne “Lee” Johnson v. Monsanto Company., Trial Team of the Year, The National Trial Lawyers Top 100, 2019
    • The National Law Journal has recognized the law firm of Baum, Hedlund, Aristei & Goldman in its 2018 Elite Trial Lawyers list for pharmaceutical litigation based on the firm’s work in a high-profile case against drug manufacturer GlaxoSmithKline., Elite Trial Lawyers, The National Law Journal, 2018
    • The Best Lawyers in America® 2016-2018
    • Listed, The Bar Register of Preeminent Lawyers™
    • Selected to: Southern California Super Lawyers® 2005, 2012-2018
    • Leader's Forum, American Association for Justice
    • Lead Counsel Rated
    • Aviation Counsel Magazine's List of Recommended High Flyers
    • Avvo.com Superb Score 10 out of 10
    • Nation’s Top One Percent, National Association of Distinguished Counsel
    • National Air Disaster Foundation Safety Award, 2002
    • AV® Preeminent 5.0 out of 5 Peer Review Rating through LexisNexis Martindale Hubbell®

    Bar/Professional Activity:

    • Plaintiffs’ Executive Committee, MDL-2741, In Re: Roundup Products Liability Litigation, 2016 -Present
    • Plaintiffs' Steering Committee, MDL 817, United Airlines Crash, Sioux City, Iowa, 1989
    • Plaintiffs' Steering Committee, MDL 1041, USAir 1016 Aircrash of Charlotte, North Carolina, 1994
    • Lead Counsel for 125 Consolidated Complex Biological-Medical Products Liability Cases, New Orleans, Louisiana, 1997
    • Plaintiffs' Steering Committee, Judicial Council Coordinated Proceedings (JCCP 4696) In re Actos Product Liability Cases, Los Angeles, California, 2012 - Present
    • Member: State Bar of California; The District of Columbia Bar; Consumer Attorneys of California; Consumer Attorneys Association of Los Angeles; American Association for Justice: Leader’s Forum; American Association for Justice: Qui Tam Litigation Group; American Association for Justice: Actos Bladder Cancer Litigation Group; American Association for Justice: Section on Toxic, Environmental, and Pharmaceutical Torts (STEP); American Association for Justice: Talcum Powder/Ovarian Cancer Litigation Group; Supporter, Public Citizen’s Civil Justice Project
    • Plaintiffs' Steering Committee, MDL 891, Northwest Airlines Crash, Detroit, 1990
    • Plaintiffs' Steering Committee, Illinois State Court Proceedings for USAir 427 Aircrash near Aliquippa, Pennsylvania, 1994
    • Plaintiffs' Steering Committee, MDL-1574, Paxil Products Liability Litigation
    • Court Admissions:California, 1985;  U.S. District Court, Central District of California, 1986;  U.S. District Court, Eastern District of California, 1989;  U.S. District Court, Northern District of California, 1989;  U.S. Court of Appeals, Ninth Circuit, 1990;  U.S. District Court, Western District of Michigan, 1991;  U.S. Supreme Court, 1991;  District of Columbia, 1993;  U.S. District Court, Northern District of Ohio, 1993;  U.S. Court of Appeals, Fourth Circuit, 1996;  U.S. District Court, Northern District of New York, 1996;  U.S. Court of Appeals, Seventh Circuit, 1997;  U.S. District Court, Western District of New York,  2009;  U.S. District Court, Eastern District of Wisconsin,  2009;  U.S. Court of Appeals, First Circuit, 2013
    • Trial Team Member, 1991-1992, United Airlines Crash, Sioux City, Iowa, 1989
    • Trial Team Member, 1997, USAir 1016 Aircrash of Charlotte, North Carolina, 1994
    • Trial Team Member, Consolidated Hemophilia-AIDS Cases, New Orleans, Louisiana, 1999

    Pro bono/Community Service:

    • Ricky Ray Hemophilia Relief Fund Act, 1998
    • Taiwan’s Ministry of Health emergency meeting regarding hemophilia HIV contaminated medication, 2004

    Scholarly Lectures/Writings:

    • Topic: “Disease Mongering and Scientific Misconduct”; Organization: Santa Monica College; Department: Visiting Lecturer in the Department of Philosophy and Social Sciences; Location: Santa Monica, California; Date: December 8, 2014
    • Topic: California’s Announcement that Roundup Causes Cancer, OEHHA, and the MDL (Multi-District Litigation); Organization: HarrisMartin; EventHarrisMartin’s Roundup® Litigation Conference AgendaLocation: Chicago, Illinois; Date: June 29, 2017
    • Topic: Actos Bladder Cancer Litigation Status Update; Panel Topic: Mass Torts: Status Update On Drug And Medical Device Litigation; Organization: Consumer Attorneys of California; Event: CAOC 52nd Annual ConventionLocation: San Francisco, California; Date: November 14-17, 2013
    • Topic: Litigation Update and Trial Analysis Roundtable: “Actos Trial Analysis”; Organization: AAJ Plaintiff Trial Lawyers and presented with Mass Torts Made Perfect; Event: AAJ Education’s Plaintiff-Only Pharmaceuticals and Medical Device Litigation Update Seminar; Location: Louisville, Kentucky; Date: May 28 – 29, 2013
    • Topic: Roundtable: Legal Issues; Organization: Selling Sickness; Event:  Selling Sickness 2013, People Before ProfitsLocation: Capitol Hill , Washington D.C.; Date: February 20 – 22, 2013
    • Topic: “Case Theories, Challenges and Case Selection Considerations for Your Actos Inventory”; Organization: HB Litigation Conferences; Event: Plaintiff Forum on Pharmaceutical Litigation, Transvaginal Mesh, Actos, and Orthopedic Devices; Location: Philadelphia, Pennsylvania; Date: October 5, 2012

    Verdicts/Settlements:

    • Dewayne Johnson v. Monsanto Company (case no. CGC-16-550128) Unanimous $289.2 million jury verdict against Monsanto Company This was a groundbreaking $289.2 million jury verdict in San Francisco Superior Court against Monsanto for causing Dewayne "Lee" Johnson's non-Hodgkin lymphoma due to exposure to a Monsanto glyphosate-based herbicide called Roundup. The jury ordered Monsanto to pay $39.2 million in compensatory damages and $250 million in punitive damages for failing to warn consumers that exposure to Roundup weed killer causes cancer. This verdict is on appeal., 2018. Mr. Johnson is represented by The Miller Firm, LLC, Baum Hedlund Aristei & Goldman, PC and Audet & Partners LLP., 2018
    • Dolin v. SmithKline Beecham Corp. et al., case number 1:12-cv-06403, in the U.S. District Court for the Northern District of Illinois. On April 20, 2017 a federal jury awarded $3 million to Wendy Dolin, resolving allegations in the trial of Dolin v. Smithkline Beecham Corp. (D/B/A GlaxoSmithKline-GSK) over the (generic Paxil) paroxetine-induced wrongful death of Wendy Dolin’s late husband, Stewart Dolin, who was a partner at the Chicago law firm Reed Smith when he took his own life in 2010. Dolin is represented by Baum Hedlund Aristei & Goldman and Rapoport Law Offices. This verdict is on appeal., 2017

    Representative Clients:

    • Ex parte Knight Ridder, Inc., 982 F.Supp. 1080 (Dist. South Carolina 1997)
    • Mason v. SmithKline Beecham  Corp., 596 F.3d 387 (7th Cir. 2010) (unanimously reversing the trial court’s preemption ruling  and allowing plaintiffs’ claims to proceed to a trial on the merits)
    • Grisham v. Philip Morris USA, 40 Cal.4th 623, 151 P.3d 1151, 54 Cal.Rptr.3d 735 (2007)
    • In re Air Crash at Charlotte, N.C. on July 2, 1994, 982 F.Supp. 1092, 1086, 1084 (Dist. South Carolina 1997)
    • Dorsett v. Sandoz, Inc., 699 F.Supp.2d 1142 (C.D.Cal. 2010) (denying defendants’ preemption motion and holding that both name-brand and generic drug manufacturers have an affirmative duty to issue warnings)
    • Grisham v. Philip Morris USA, 482 F. 3d 1131 (9th Cir. 2007)
    • Smith v. Cutter Biological, 770 So. 2d 392 (La. App. 4th Cir. 2000)
    • In re Air Crash at Charlotte, N.C. on July 2, 1994, 982 F.Supp. 1071, 1060, 1056, 1052 (Dist. South Carolina 1995 & 1996)
    • Collins v. SmithKline Beecham Corp., 2008 WL 744070 (Pa. Ct.Com.Pl. March 11, 2008)
    • Grisham v. Philip Morris USA, 403 F. 3d 631 (9th Cir. 2005)

    Other Outstanding Achievements:

    • Taiwan’s Ministry of Health emergency meeting regarding hemophilia HIV contaminated medication, 2004

    Educational Background:

    • University of California, Los Angeles, B.A., summa cum laude, 1982

    Industry Groups

    • Catastrophic Injury
    • Class Actions
    • Complex And Multi-District Litigation
    • Medical Device
    • Personal Injury
    • Pharmaceutical Drug Product Liability
    • Product Liability
    • Qui Tam Claims
    • Whistleblower Protection
    • Wrongful Death Law
    Show More
    Office Location for Michael L. Baum

    10940 Wilshire Blvd.
    17th Floor
    Los Angeles, CA 90024

    Phone: 310-207-3233

    Fax: 310-820-7444

    Michael L. Baum:

    Last Updated: 7/21/2020

    Page Generated: 0.61600089073181 sec